secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2026-08-06T20:03:19+00:00
Accession:  0001714899-26-000096
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Q2 net loss $127.6M; AVLAYAH revenue $3.6M; PRV sale adds $195M; DNL151 discontinued in idiopathic PD
--------------------------------------------------------------------------------

- Q2 2026 net loss $127.6M vs $124.1M YoY; R&D $97.0M, SG&A $36.3M.
- AVLAYAH (Hunter syndrome) first full quarter net revenue $3.6M; Q3 guidance $10-12M.
- PRV sale closed July 2026 for $195M gross; pro forma cash >$1.1B.
- DNL151 (Parkinson's) Phase 2b LUMA failed; development in idiopathic PD discontinued; BEACON study for LRRK2 carriers continues.
- DNL593 (FTD-GRN) results delayed to 2027; Takeda terminated collaboration in April (strategic).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489926000096/0001714899-26-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489926000096/dnli-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001714899-26-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer